CO5090882A1 - Nueva vacuna y procedimiento de uso des transmitidas sexualmente - Google Patents

Nueva vacuna y procedimiento de uso des transmitidas sexualmente

Info

Publication number
CO5090882A1
CO5090882A1 CO99057608A CO99057608A CO5090882A1 CO 5090882 A1 CO5090882 A1 CO 5090882A1 CO 99057608 A CO99057608 A CO 99057608A CO 99057608 A CO99057608 A CO 99057608A CO 5090882 A1 CO5090882 A1 CO 5090882A1
Authority
CO
Colombia
Prior art keywords
sexually transmitted
use procedure
woman
new vaccine
std
Prior art date
Application number
CO99057608A
Other languages
English (en)
Spanish (es)
Inventor
Mohamed Slaoul Moncef
G Vandepapelie Pierre
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10838766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5090882(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CO5090882A1 publication Critical patent/CO5090882A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CO99057608A 1998-09-11 1999-09-10 Nueva vacuna y procedimiento de uso des transmitidas sexualmente CO5090882A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9819898A GB9819898D0 (en) 1998-09-11 1998-09-11 New vaccine and method of use

Publications (1)

Publication Number Publication Date
CO5090882A1 true CO5090882A1 (es) 2001-10-30

Family

ID=10838766

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99057608A CO5090882A1 (es) 1998-09-11 1999-09-10 Nueva vacuna y procedimiento de uso des transmitidas sexualmente

Country Status (28)

Country Link
EP (1) EP1109574B1 (https=)
JP (1) JP2002524532A (https=)
KR (1) KR100777896B1 (https=)
CN (2) CN1325311A (https=)
AR (1) AR021798A1 (https=)
AT (1) ATE392214T1 (https=)
AU (1) AU744989B2 (https=)
BR (1) BR9913630A (https=)
CA (1) CA2343399C (https=)
CO (1) CO5090882A1 (https=)
CY (1) CY1108147T1 (https=)
CZ (1) CZ302808B6 (https=)
DE (1) DE69938555T2 (https=)
DK (1) DK1109574T3 (https=)
ES (1) ES2304068T3 (https=)
GB (1) GB9819898D0 (https=)
HU (1) HUP0104297A3 (https=)
IL (1) IL141843A0 (https=)
MY (1) MY122216A (https=)
NO (1) NO329522B1 (https=)
NZ (1) NZ510425A (https=)
PL (1) PL199545B1 (https=)
PT (1) PT1109574E (https=)
SI (1) SI1109574T1 (https=)
TR (1) TR200100948T2 (https=)
TW (1) TWI225790B (https=)
WO (1) WO2000015255A1 (https=)
ZA (1) ZA200101987B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
AU2007281934B2 (en) 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
KR101621837B1 (ko) 2007-09-12 2016-05-17 노파르티스 아게 Gas57 돌연변이 항원 및 gas57 항체
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2011008400A2 (en) 2009-06-16 2011-01-20 Novartis Ag High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
EP2556377B1 (en) 2010-04-08 2017-07-12 University of Pittsburgh - Of the Commonwealth System of Higher Education B-cell antigen presenting cell assay
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
EP2726097A4 (en) * 2011-07-01 2015-03-11 Univ California HERPES VIRUS VACCINE AND METHOD OF USE
AU2015287994B2 (en) * 2014-07-07 2020-03-12 Prophylaxis, Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
US11071745B2 (en) 2014-07-07 2021-07-27 Elian Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
JP7005504B2 (ja) 2016-02-22 2022-01-21 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 生体分子の固定化方法
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5776468A (en) * 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date
NO20011193D0 (no) 2001-03-08
HUP0104297A3 (en) 2004-10-28
TR200100948T2 (tr) 2001-07-23
DE69938555T2 (de) 2009-06-10
ATE392214T1 (de) 2008-05-15
NO329522B1 (no) 2010-11-01
JP2002524532A (ja) 2002-08-06
EP1109574B1 (en) 2008-04-16
AU744989B2 (en) 2002-03-07
ZA200101987B (en) 2002-05-09
IL141843A0 (en) 2002-03-10
HK1037978A1 (en) 2002-03-01
AR021798A1 (es) 2002-08-07
NZ510425A (en) 2003-04-29
DK1109574T3 (da) 2008-06-30
HUP0104297A2 (hu) 2002-03-28
ES2304068T3 (es) 2008-09-01
CZ2001887A3 (cs) 2001-10-17
KR100777896B1 (ko) 2007-11-27
MY122216A (en) 2006-03-31
WO2000015255A1 (en) 2000-03-23
CA2343399A1 (en) 2000-03-23
PL346651A1 (en) 2002-02-25
EP1109574A1 (en) 2001-06-27
AU5975299A (en) 2000-04-03
BR9913630A (pt) 2001-05-22
CN1325311A (zh) 2001-12-05
NO20011193L (no) 2001-05-09
PT1109574E (pt) 2008-06-12
CY1108147T1 (el) 2014-02-12
KR20010075049A (ko) 2001-08-09
PL199545B1 (pl) 2008-09-30
SI1109574T1 (sl) 2008-08-31
CA2343399C (en) 2010-08-03
CN101130070A (zh) 2008-02-27
TWI225790B (en) 2005-01-01
CZ302808B6 (cs) 2011-11-23
GB9819898D0 (en) 1998-11-04
DE69938555D1 (de) 2008-05-29

Similar Documents

Publication Publication Date Title
CO5090882A1 (es) Nueva vacuna y procedimiento de uso des transmitidas sexualmente
YU47899B (sh) Postupak za dobivanje preparata koji sprečava prenošenje polnih bolesti i tampona koji ga sadrži
HUP9801560A1 (hu) Szaponint és szterint tartalmazó vakcinák
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
CO5200837A1 (es) Vacunas
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
BR9608648A (pt) Vacinas de vírus vivos prrs de baixa patogenicidade processos para sua preparação
AU4358801A (en) Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
AR020050A1 (es) COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE LA ENFERMEDAD AMILOIDOGENICA USO DE UN PÉPTIDO ABETA PARA LA PREPARACIoN DE MEDICAMENTOS
PT1296711E (pt) E7 de vph para o tratamento do virus do papiloma humano
DE60215373D1 (de) Vorrichtung zur abgabe von mikrodosen eines medikaments in das ohr
BR0114392A (pt) Formulação de vacina, método para produzir uma formulação de vacina, uso de uma preparação de vacina contra rsv dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por rsv
MX173567B (es) Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih
PT1024824E (pt) Composicao de vacina dispersivel solida para administracao oral
BR0309181A (pt) Preservativo
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
Rudy Imiquimod (Aldara): modifying the immune response
EA199700150A1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ВИЧ ИНФЕКЦИИ С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА ПРОТЕАЗЫ ВИЧ ИНДИНАВИРА И ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ 3TC, НЕОБЯЗАТЕЛЬНО СОВМЕСТНО С AZT, ddI ИЛИ ddC
NZ505538A (en) A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma
ES2151922T3 (es) Uso de aspirina para la fabricacion de un medicamento para mejorar la perfusion sanguinea en el utero.
Chang Genital herpes and type 1 herpesvirus hominis
HUP9901299A2 (hu) Attenuált, nemimmunogén poxvírusokból vagy parapoxvírusokból előállított multipotens parapox immunitást előidéző gyógyszerek használatának új indikációi
AR034037A1 (es) Inhibidor de aromatasa en dosis multiples para tratar la infertilidad
BR0207899A (pt) Imunógeno de combinação para administração sequencial dos componentes para evocar uma resposta imune contra o papilomavìrus, produto farmacêutico, uso de um produto farmacêutico, e, método para evocar uma resposta imune contra o papilomavìrus em um paciente